Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients | Zendy

Jukun Wang | Zendy; Ke Han | Zendy; Chao Zhang | Zendy; Xin Chen | Zendy; Yu Li | Zendy; Linzhong Zhu | Zendy; Tao Luo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients

Author(s) -

Jukun Wang,

Ke Han,

Chao Zhang,

Xin Chen,

Yu Li,

Linzhong Zhu,

Tao Luo

Publication year - 2021

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20210583

Subject(s) - adme , kegg , hepatocellular carcinoma , computational biology , biology , oncology , proportional hazards model , gene , lasso (programming language) , bioinformatics , medicine , transcriptome , genetics , gene expression , pharmacokinetics , computer science , world wide web

ADME genes are genes involved in drug absorption, distribution, metabolism, and excretion (ADME). Previous studies report that expression levels of ADME-related genes correlate with prognosis of hepatocellular carcinoma (HCC) patients. However, the role of ADME gene expression on HCC prognosis has not been fully explored. The present study sought to construct a prediction model using ADME-related genes for prognosis of HCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research